TW202146651A - miR-33b阻礙物質所致之動脈瘤的預防或治療 - Google Patents
miR-33b阻礙物質所致之動脈瘤的預防或治療 Download PDFInfo
- Publication number
- TW202146651A TW202146651A TW110107244A TW110107244A TW202146651A TW 202146651 A TW202146651 A TW 202146651A TW 110107244 A TW110107244 A TW 110107244A TW 110107244 A TW110107244 A TW 110107244A TW 202146651 A TW202146651 A TW 202146651A
- Authority
- TW
- Taiwan
- Prior art keywords
- mir
- nucleic acid
- modified
- antisense oligonucleotide
- therapeutic agent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-034619 | 2020-03-02 | ||
| JP2020034619 | 2020-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202146651A true TW202146651A (zh) | 2021-12-16 |
Family
ID=77613063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110107244A TW202146651A (zh) | 2020-03-02 | 2021-03-02 | miR-33b阻礙物質所致之動脈瘤的預防或治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230159924A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4129338A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7773730B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096420B (cg-RX-API-DMAC7.html) |
| AR (1) | AR121490A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202146651A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021177267A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4331606A4 (en) * | 2021-04-30 | 2025-05-07 | Kyoto University | PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR |
| WO2022260162A1 (ja) * | 2021-06-11 | 2022-12-15 | 国立大学法人京都大学 | Nashの予防及び/又は治療剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| CA3042781C (en) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2010120508A2 (en) * | 2009-03-31 | 2010-10-21 | The General Hospital Corporation | Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders |
| AU2010312751B2 (en) | 2009-10-29 | 2014-07-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| WO2012027601A2 (en) * | 2010-08-25 | 2012-03-01 | The General Hospital Corporation | Methods targeting mir-33 micrornas for regulating lipid metabolism |
-
2021
- 2021-03-02 JP JP2022504376A patent/JP7773730B2/ja active Active
- 2021-03-02 CN CN202180018696.9A patent/CN116096420B/zh active Active
- 2021-03-02 AR ARP210100539A patent/AR121490A1/es not_active Application Discontinuation
- 2021-03-02 EP EP21763528.3A patent/EP4129338A4/en active Pending
- 2021-03-02 TW TW110107244A patent/TW202146651A/zh unknown
- 2021-03-02 WO PCT/JP2021/007822 patent/WO2021177267A1/ja not_active Ceased
- 2021-03-02 US US17/905,442 patent/US20230159924A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4129338A1 (en) | 2023-02-08 |
| EP4129338A4 (en) | 2024-04-10 |
| CN116096420A (zh) | 2023-05-09 |
| JPWO2021177267A1 (cg-RX-API-DMAC7.html) | 2021-09-10 |
| JP7773730B2 (ja) | 2025-11-20 |
| AR121490A1 (es) | 2022-06-08 |
| WO2021177267A1 (ja) | 2021-09-10 |
| US20230159924A1 (en) | 2023-05-25 |
| CN116096420B (zh) | 2026-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022078069A (ja) | 二本鎖RNAによるα-1アンチトリプシンの特異的阻害のための方法及び組成物 | |
| TW201723176A (zh) | Kras表現之調節劑 | |
| EA015563B1 (ru) | Короткая внутренне сегментированная интерферирующая рнк | |
| EP2683411B1 (en) | Methods of using microrna-26a to promote angiogenesis | |
| US20250327070A1 (en) | Compositions and methods for inhibiting complement factor b | |
| KR20150004414A (ko) | Kras-관련 질환을 치료하기 위한 유기 조성물 | |
| JP2025100729A (ja) | 補体成分3の発現を阻害するための組成物及び方法 | |
| US10378014B2 (en) | Compositions and methods for the treatment of influenza infection | |
| CA3215836A1 (en) | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression | |
| JP2024002985A (ja) | 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法 | |
| JP7773730B2 (ja) | miR-33b阻害物質による動脈瘤の予防または治療 | |
| JP2016501533A (ja) | 二本鎖rnaによるckap5の特異的阻害に関する方法および組成物 | |
| US12421552B2 (en) | MicroRNA-134 biomarker | |
| JP2009516710A (ja) | eIF4E−BP2の発現のモジュレート | |
| JP2022520653A (ja) | Cyp27a1の発現を阻害するための方法及び組成物 | |
| JP2023036061A (ja) | miR-33b阻害物質による動脈瘤の予防または治療 | |
| US7528117B2 (en) | High efficacy antisense RIαPKA poly-DNP oligoribonucleotides | |
| EP4331606A1 (en) | Prevention or treatment of myopathy using mir-33b inhibitor | |
| HK40035697A (en) | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors | |
| HK40044009A (en) | Microrna-134 biomarker | |
| NZ623459B2 (en) | Micrornas in neurodegenerative disorders |